AgeneBio Receives Grant for Drug-Discovery Program Targeting Cognitive Decline in Alzheimer’s

AgeneBio Receives Grant for Drug-Discovery Program Targeting Cognitive Decline in Alzheimer’s
AgeneBio has received a $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of a novel GABAA discovery program targeting hippocampal overactivity in the brain, which is thought to contribute to neurodegeneration and cognitive decline in Alzheimer’s disease (AD) patients. AgeneBio’s pipeline of therapies is based on research showing that overactivity in the

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *